Shares of Nektar Therapeutics (NASDAQ:NKTR) have earned a consensus recommendation of “Buy” from the thirteen research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $27.11.

A number of research analysts recently weighed in on the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $23.00 target price on shares of Nektar Therapeutics in a research report on Friday, July 21st. Roth Capital set a $33.00 target price on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. BidaskClub downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Evercore ISI assumed coverage on shares of Nektar Therapeutics in a research report on Thursday, August 17th. They issued an “in-line” rating and a $20.00 target price for the company. Finally, William Blair reaffirmed an “outperform” rating on shares of Nektar Therapeutics in a research report on Tuesday, July 18th.

WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/nektar-therapeutics-nktr-receives-27-11-average-pt-from-brokerages/1648175.html.

In other news, CAO Jillian B. Thomsen sold 2,648 shares of Nektar Therapeutics stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $19.32, for a total value of $51,159.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Stephen K. Doberstein sold 43,677 shares of Nektar Therapeutics stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $24.97, for a total transaction of $1,090,614.69. The disclosure for this sale can be found here. In the last three months, insiders sold 539,983 shares of company stock valued at $12,388,528. Insiders own 6.10% of the company’s stock.

Several hedge funds have recently made changes to their positions in the stock. Gs Investments Inc. bought a new stake in shares of Nektar Therapeutics during the 2nd quarter worth about $1,006,000. Piedmont Investment Advisors LLC boosted its holdings in shares of Nektar Therapeutics by 264.6% during the 2nd quarter. Piedmont Investment Advisors LLC now owns 33,545 shares of the biopharmaceutical company’s stock worth $656,000 after buying an additional 24,344 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in shares of Nektar Therapeutics by 7.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 13,011 shares of the biopharmaceutical company’s stock worth $254,000 after buying an additional 929 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Nektar Therapeutics by 3.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 114,357 shares of the biopharmaceutical company’s stock worth $2,235,000 after buying an additional 3,683 shares during the period. Finally, Redmile Group LLC bought a new stake in shares of Nektar Therapeutics during the 2nd quarter worth about $285,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Shares of Nektar Therapeutics (NASDAQ:NKTR) traded up 2.07% during midday trading on Thursday, reaching $24.16. 1,111,426 shares of the company were exchanged. Nektar Therapeutics has a 52-week low of $11.41 and a 52-week high of $25.02. The stock has a 50-day moving average price of $23.01 and a 200 day moving average price of $20.46. The company’s market capitalization is $3.78 billion.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). The business had revenue of $34.60 million during the quarter, compared to the consensus estimate of $33.64 million. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period last year, the business posted ($0.36) EPS. Equities research analysts expect that Nektar Therapeutics will post ($0.98) EPS for the current fiscal year.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.